Ali Esfandiary

ORCID: 0000-0003-0122-3575
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • vaccines and immunoinformatics approaches
  • Immunotherapy and Immune Responses
  • RNA Interference and Gene Delivery
  • Cancer, Hypoxia, and Metabolism
  • Cancer Research and Treatments
  • Atherosclerosis and Cardiovascular Diseases
  • Immune Cell Function and Interaction
  • Parkinson's Disease Mechanisms and Treatments
  • Adipose Tissue and Metabolism
  • Cancer-related Molecular Pathways
  • Cellular transport and secretion
  • Multiple Myeloma Research and Treatments
  • Lysosomal Storage Disorders Research
  • Adipokines, Inflammation, and Metabolic Diseases

Monash University
2022

Australian National Fabrication Facility
2022

Melbourne Centre for Nanofabrication
2022

Shahid Beheshti University of Medical Sciences
2015-2017

Hypoxia-Inducible Factor (HIF)-1 plays an essential role in the body's response to low oxygen concentrations and regulates expression of several genes implicated homeostasis, vascularization, anaerobic metabolism as well immunological responses. Increased levels HIF-1α are associated with increased proliferation more aggressive breast tumor development. Lactobacilli have been shown exert anti-cancer effects on malignancies including cancer. However, exact mechanism such effect is not clear...

10.22074/cellj.2016.4319 article EN DOAJ (DOAJ: Directory of Open Access Journals) 2016-08-20

Acute coronary syndrome (ACS) is the most serious form of artery disease. Inflammatory processes participate in different stages this disorder. FOXP3 gene plays an important role for development and function regulatory T cells. Consequently, expression level polymorphisms have been studied many immune related diseases. In present study, we analysed as well association between two variants (rs3761548A/C rs5902434del/ATT) occurrence ACS Iranian patients. analysis showed a significant decrease...

10.1002/cbf.3174 article EN Cell Biochemistry and Function 2016-02-29
Coming Soon ...